Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens

Open Access
Publisher Website
Google Scholar
Abstract
GAR-936 is a new semisynthetic glycylcycline with a broad antibacterial spectrum, including tetracycline-resistant strains. The in vitro activities of GAR-936, minocycline, doxycycline, tetracycline, moxifloxacin, penicillin G, and erythromycin were determined by agar dilution methods against 268 aerobic and 148 anaerobic strains of bacteria (including Pasteurella , Eikenella , Moraxella , Bergeyella , Neisseria , EF-4, Bacteroides , Prevotella , Porphyromonas , Fusobacterium , Staphylococcus , Streptococcus , Enterococcus , Corynebacterium , Propionibacterium , Peptostreptococcus , and Actinomyces ) isolated from infected human and animal bite wounds in humans, including strains resistant to commonly used antimicrobials. GAR-936 was very active, with an MIC at which 90% of the strains are inhibited (MIC 90 ) of ≤0.25 μg/ml, against all aerobic gram-positive and -negative strains, including tetracycline-resistant strains of Enterococcus , Streptococcus , and coagulase-negative staphylococci, except for Eikenella corrodens (MIC 90 , ≤4 μg/ml). GAR-936 was also very active against all anaerobic species, including tetracycline-, doxycycline-, and minocycline-resistant strains of Prevotella spp., Porphyromonas spp., Bacteroides tectum , and Peptostreptococcus spp., with an MIC 90 of ≤0.25 μg/ml. Erythromycin- and moxifloxacin-resistant fusobacteria were susceptible to GAR-936, with an MIC 90 of 0.06 μg/ml.